Medinice (WAR:ICE) Research & Development: zł0.00 Mil (TTM As of Mar. 2026)


WAR:ICE Medinice SA WAR:ICE
24 GF Score
Price zł75.00
GF Value zł0.99
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Medinice Research & Development?

Medinice WAR:ICE +8.70% 24 Research & Development is zł0.00 Mil as of Mar. 2026. GuruFocus rates WAR:ICE with a GF Score™ of 24/100 and a GF Value™ of zł0.99 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medinice's Research & Development for the three months ended in Mar. 2026 was zł0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.00 Mil.

Medinice  (WAR:ICE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medinice Research & Development Related Terms

Medinice Research & Development Historical Data

* Premium members only.

The historical data trend for Medinice's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medinice Research & Development Chart

Medinice Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medinice Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WAR:ICE
24GF Score
Medinice SA WAR:ICE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medinice Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of zł0.00 Mil mean?
Medinice (WAR:ICE) has a Research & Development of zł0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Medinice and its competitors.
Is Medinice's Research & Development too high?
Medinice's current Research & Development is zł0.00 Mil. Overall, Medinice has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medinice's Research & Development compare to ABT and SYK?
Medinice's Research & Development of zł0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medinice and its competitors. Medinice's current Research & Development is zł0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinice stock overvalued right now?
Based on GuruFocus' analysis, Medinice (WAR:ICE) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.99, compared to a current price of zł75.00 — trading 7475.8% above its estimated fair value. The current Research & Development is zł0.00 Mil. Medinice's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medinice (WAR:ICE), the current Research & Development is zł0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medinice (WAR:ICE) Overvalued in 2026?

Based on GuruFocus' analysis, Medinice stock appears to be overvalued. The current stock price of zł75.00 is trading 7475.8% above its estimated GF Value™ of zł0.99. GuruFocus considers Medinice to be Significantly Overvalued.

Key valuation signals for WAR:ICE:

  • Research & Development: zł0.00 Mil
  • GF Value™: zł0.99 vs. price of zł75.00 (7475.8% above fair value)
  • GF Score™: 24/100 with 1 warning sign

No single metric tells the full story. See the WAR:ICE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medinice Business Description

Other Exchanges 77E:Germany
Address Hankiewicza Street 2, Warszawa, POL, 02-103
Medinice SA is a Polish company operating in the MedTech industry. The company is engaged in creating, developing and commercializing solutions in the field of medicine, in particular, cardiology and cardio surgery. Its portfolio includes close around 12 projects including CathAIO, an electrode with universal diagnostic, electrophysiological, haemodinamic and biohemic functions and can be used for RF ablation; cryoapplicator, for minimally invasive cardiosurgical cryoablation; Med-iConsole allows to reduce the need to use multiple computer devices during electrophysiological treatment; Minimax and Pacepress.
24GF Score

Get the complete analysis for WAR:ICE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł75.00
Price
zł0.99
GF Value